All studies
RecruitingPHASE1, PHASE2INTERVENTIONAL

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

Late-onset Pompe disease is a rare genetic condition that causes muscle weakness and breathing problems over time. It happens because the body cannot properly break down a stored sugar called glycogen, which then builds up inside muscle cells. This early-stage clinical trial is testing an experimental medicine called DNL952 in adults aged 18 to 75. The main goal is to find out whether DNL952 is safe and well tolerated across different dose levels. Researchers also want to learn how the body breaks down the medicine and what effect it has on the disease. Depending on the group you join, you may be eligible if you are already receiving standard enzyme therapy, or if you have never had regular enzyme therapy before. Everyone in this study receives the active medicine, with careful health monitoring throughout.

At a glance

Status
Recruiting
Phase
PHASE1, PHASE2
Sponsor
Denali Therapeutics Inc.
Enrolment target
32
Start
12 May 2026
Estimated completion
01 Aug 2028

What is this study about?

Late-onset Pompe disease is a rare, inherited condition. People with this condition do not have enough of an important enzyme needed to break down glycogen, a type of sugar stored in cells. Over time, this sugar accumulates in the muscles, causing gradual weakness in the legs, arms, and the muscles that help you breathe.

Currently, many people with Pompe disease take enzyme replacement therapy through a regular drip to replace the missing enzyme. Scientists are developing DNL952 as a potential new treatment. This clinical trial is designed to test DNL952 in humans to see if it is safe, how different doses affect the body, and how long the medicine stays in the system.

This is an 'open-label' study, which means both you and the study doctors will know you are receiving DNL952. Finding safe and effective new treatments is essential for providing better long-term options for people living with muscle weakness caused by Pompe disease.

Key takeaways

  • Tests a new investigational medicine, DNL952, for late-onset Pompe disease.
  • Aims to check the safety of the drug and find the best doses.
  • Open to adults aged 18 to 75 who can walk at least 40 metres with or without walking aids.
  • Includes both people currently on certain enzyme therapies and people new to treatment.
  • All participants receive the study drug; there is no placebo.

Who may be eligible?

This study is open to adults aged 18 to 75 with a confirmed diagnosis of late-onset Pompe disease who weigh at least 40 kg (around 6 stone 4 lbs). To take part, you must be able to walk at least 40 metres, though you are welcome to use walking aids like sticks or frames. Your breathing function must also meet a minimum standard, meaning your lung capacity while sitting upright is at least 30% of normal.

The trial has different groups based on your treatment history. One group is for people who have been on a stable dose of specific enzyme replacement therapies (such as avalglucosidase alfa or cipaglucosidase alfa) for at least six months. Another group is for people who have not had regular enzyme replacement therapy.

You cannot take part if you rely fully on a wheelchair or need daytime breathing support with a mask for more than six hours while awake (night-time breathing support during sleep is allowed). People with uncontrolled major illnesses or those who have previously had gene therapy are also unable to join.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am between 18 and 75 years of age.
  2. I have a confirmed diagnosis of late-onset Pompe disease.
  3. I weigh at least 40 kg (6 stone 4 lbs).
  4. I can walk at least 40 metres (walking aids are allowed).
  5. I do not rely entirely on a wheelchair.
  6. I do not use a breathing machine for more than 6 hours during the daytime while awake.
Answer every question to see your result.

What does participation involve?

If you take part, you will receive regular doses of DNL952 at a specialist study clinic. During your visits, the medical team will carry out health checks to see how you are doing. These checks will include blood and urine tests, heart traces (ECGs), walking assessments, and lung function tests to measure your breathing. The doctors will also closely monitor how your body processes the medicine and watch for any side effects. Your study team will explain the exact schedule of visits, how often you receive the medicine, and the overall length of the trial before you decide to join.

Potential risks and benefits

Taking part may not improve your condition directly, as this is an early-stage safety study. However, the information gathered could help improve treatments for people with Pompe disease in the future. As with any new medicine, there is a risk of side effects or allergic reactions to the drug. Attending regular hospital visits and having tests like blood draws may also take time and cause mild discomfort. Joining the study is completely voluntary. You can choose to leave at any time without giving a reason, and your regular NHS medical care will not be affected.

Locations (8)

  • University of California-Irvine
    Verified postcode
    Irvine, United States· Recruiting
  • Washington University School of Medicine
    Verified postcode
    St Louis, United States· Recruiting
  • Duke University School of Medicine - Early Phase Research Unit
    Verified postcode
    Durham, United States· Recruiting
  • The Lysosomal & Rare Disorders Research & Treatment Center
    Verified postcode
    Fairfax, United States· Recruiting
  • SphinCS GmbH
    Verified postcode
    Höchheim, Germany· Recruiting
  • Erasmus Medical Center
    Verified postcode
    Rotterdam, Netherlands· Recruiting
  • Royal Free Hospital NHS Trust
    Verified postcode
    London, United Kingdom· Recruiting
  • Salford Care Organisation Northern Care Alliance NHS Group
    Verified postcode
    Manchester, United Kingdom· Recruiting

Common questions

Will I receive a dummy drug (placebo)?

No. This is an open-label trial, meaning there is no placebo. Every participant receives the active study medicine, DNL952.

Can I use a walking frame or stick during the walking test?

Yes. You can use your usual walking aids, such as crutches, sticks, or frames, to complete the 40-metre walking assessment.

Can I join if I use a breathing machine at night?

Yes. Using non-invasive breathing support (like a CPAP or BiPAP machine) while sleeping is allowed. However, needing breathing support for more than six hours during the daytime while awake is not permitted.

What happens if I am already taking an enzyme replacement therapy?

Depending on the exact medication you take and how long you have been on it, you may be eligible for a specific group in this study. The study team can check if your current treatment qualifies.

Do I have to pay to take part?

No. Clinical trial medication and study-related tests are provided free of charge. Travel expenses to and from the clinic are often covered as well.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Study to Evaluate the Safety, Pharmacokinetics, and Pharma…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.